It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Complement activation on cell surfaces leads to the massive deposition of C3b, iC3b, and C3dg, the main complement opsonins. Recognition of iC3b by complement receptor type 3 (CR3) fosters pathogen opsonophagocytosis by macrophages and the stimulation of adaptive immunity by complement-opsonized antigens. Here, we present the crystallographic structure of the complex between human iC3b and the von Willebrand A inserted domain of the α chain of CR3 (αI). The crystal contains two composite interfaces for CR3 αI, encompassing distinct sets of contiguous macroglobulin (MG) domains on the C3c moiety, MG1-MG2 and MG6-MG7 domains. These composite binding sites define two iC3b-CR3 αI complexes characterized by specific rearrangements of the two semi-independent modules, C3c moiety and TED domain. Furthermore, we show the structure of iC3b in a physiologically-relevant extended conformation. Based on previously available data and novel insights reported herein, we propose an integrative model that reconciles conflicting facts about iC3b structure and function and explains the molecular basis for iC3b selective recognition by CR3 on opsonized surfaces.
Complement activation on foreign cell surfaces leads to the generation of complement opsonins, which activate complement receptor type 3 (CR3) and pathogen clearance by macrophages. Here, the authors reveal structural basis of the interaction between human opsonin iC3b and the von Willebrand A inserted domain of the α chain of CR3.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Abvance Biotech srl, Madrid, Spain (GRID:grid.4711.3)
2 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846)
3 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain (GRID:grid.4711.3); Vanderbilt University Medical Center, Division of Genetic Medicine, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
4 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain (GRID:grid.4711.3)
5 L’Orme des Merisiers Saint-Aubin, Synchrotron SOLEIL, Gif-sur-Yvette, France (GRID:grid.426328.9)